The Future of Drug-Pricing Transparency

Amid the release of the Trump administration’s “Transparency in Coverage” Final Rule requiring disclosure of drug prices, the authors arguing that while drug-pricing transparency enjoys bipartisan support, key debates remain about whether disclosure of confidential rebates will empower payers to negotiate better prices or allow manufacturers to push net prices higher.